FDA Grants Fast Track Designation to SGX942 for the Treatment of Oral Mucositis
The FDA has granted fast track designation to the SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in patients with head and neck cancer.
SGX942 is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability and simultaneous anti-inflammatory and anti-infective activity. The agent has demonstrated safety in a phase I clinical study and efficacy in animal disease models.
Fast track designation is designed to facilitate the development and expedite the review of new drugs intended to treat a serious or life-threatening condition and that demonstrates the potential to address an unmet medical need for the condition.
SGX942 is developed by Soligenix.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
